Competitive Enterprise Institute | 1899 L ST NW Floor 12, Washington, DC 20036 | Phone: 202-331-1010 | Fax: 202-331-0640
Charging that outgoing FDA Commissioner David Kessler has left a legacy of increased bureaucracy and deadly overcaution, the Competitive Enterprise Institute will release a new study which presents a list of promising drugs and devices currently unavailable or delayed in the U.S.
"While many are singing Kessler's praises for supposedly speeding up drug and device approvals, we want to remind the public that FDA continues to prevent life saving therapies from coming to this country," said Julie DeFalco, CEI Policy Analyst and author of the new study, Treatment Delayed, Treatment Denied: Therapeutic Lag and the FDA's Performance.
Some of those drugs and medical devices include:
"The FDA claims that it is approving more therapies faster than ever, and that is clearly not true," said DeFalco. "The FDA also alleges that important new therapies are not being kept from Americans, an assertion which, sadly, is false as well."
For more information, contact Greg Smith at (202) 331-1010 or gsmith@CEI.org .